A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Odanacatib (Primary)
- Indications Breast cancer; Cancer metastases
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 11 Aug 2016 Planned End Date changed from 1 Aug 2008 to 1 Sep 2008.
- 11 Aug 2016 Planned primary completion date changed from 1 Aug 2008 to 1 Sep 2008.
- 15 Mar 2012 Trial location (Spain) identified as reported by EudraCT.